• Mutation; HGNC; HGNC:7765; NF1; Simple; p.Gln28Ter (c.82C>T); ClinVar=VCV000429015; Zygosity=Homozygous (PubMed=30737244).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Asn29Thrfs*15 (c.86delA); ClinVar=VCV000528243; Zygosity=Homozygous (PubMed=30737244).
  

PubMed=17406368; DOI=10.1038/sj.bjc.6603578; PMCID=PMC2360140
Ricardo F. Rodrigues, Lucia Roque, Tami Krug, Valeriano Leite;
Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines.
Br. J. Cancer 96:1237-1245(2007)

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Inigo Landa, Ian Ganly, Timothy A. Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A. Ghossein, James Alexander Fagin;
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896
Manoj Garg, Ryoko Okamoto, Yasunobu Nagata, Deepika Kanojia, Subhashree Venkatesan, Mayakonda Thippeswamy Anand, Glenn D. Braunstein, Jonathan William Said, Ngan B. Doan, Quoc Ho, Tadayuki Akagi ...Show all 18 authors... , Sigal Gery, Li-Zhen Liu, Kar-Tong Tan, Wee Joo Chang, Henry He Yang, Seishi Ogawa, Harold Phillip Koeffler; Show fewer authors
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Inigo Landa, Nikita Pozdeyev, Christopher T. Korch, Laura A. Marlow, Robert Christian Smallridge, John Alton Copland 3rd, Ying C. Henderson, Stephen Y. Lai, Gary L. Clayman, Naoyoshi Onoda, Aik-Choon Tan ...Show all 16 authors... , Maria E.R. Garcia-Rendueles, Jeffrey A. Knauf, Bryan R. Haugen, James Alexander Fagin, Rebecca E. Schweppe; Show fewer authors
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)